Answers are grounded in this paper and cite their sources.
Key points Hyperprolactinemia (HPRL) is a cause of menstrual irregularity, galactorrhea, hypogonadism and infertility.Recognizing the cause of HPRL is essential to institute appropriate treatment. Drug treatment with dopamine agonist (DA) is the first line of therapy for symptomatic HPRL due to prolactinoma or idiopathic HPRL. Dopamine agonist treatment is effective in 80-90% of cases. Infertility treatment in patients with HPRL is also carried out with DA, aiming to normalize prolactin (PRL) levels. The risk of symptomatic growth of prolactinomas during pregnancy is related to the size of the tumor, length of previous treatment and higher PRL levels, and is less than 5% in microprolactinomas. Hyperprolactinemia remission can occur after pregnancy and menopause, and in around 30% of cases following drug treatment. The use of drugs such as antidepressants and antipsychotics is a frequent cause of HPRL, and has particularities in its management. Recommendations The initial treatment of patients with HPRL caused by prolactinoma or idiopathic HPRL is with medication and DAs are the option of choice.Cabergoline (CAB) is more effective and better tolerated than bromocriptine (BRC), representing the first therapeutic choice. Treatment should begin with lower doses with slow progression for better tolerability.The use of high doses requires attention to potential side effects and psychiatric effects, as well as monitoring for heart valve disease. In cases of good control of symptoms, PRL levels and the size of the prolactinoma with DAs, a minimum of two years of treatment is recommended before starting to reduce the dose and withdraw the medication. In symptomatic patients, surgical treatment of prolactinomas may be indicated in cases of intolerance or resistance to DAs. The symptomatic growth of microadenomas is not frequent during pregnancy.Dopamine agonist can be withdrawan in cases of idiopathic HPRL, microadenomas and intrasellar macroadenomas that showed good tumor control after at least one year of drug treatment before pregnancy. Tumors diagnosed during menacme and with good control with DA can generally have treatment discontinued with menopause. The status of the prolactinoma must be re-evaluated with sellar imaging after one to two years of treatment with DA, after pregnancy and after menopause.The exception are macroadenomas with compressive risk or inadequate response that must be individually re-evaluated. The patient should be referred to specialists in cases of HPRL by stalk disconnection, acromegaly, resistant and aggressive prolactinoma, and in cases of hypopituitarism. For pharmacological causes, the patient should be referred to the prescriber physician so they can evaluate whether to suspend or replace the drug.If this is not possible, pituitary imaging should be performed to rule out a tumor and hormone replacement containing estrogen should be considered to reduce risks whenever there is hypogonadism.
No takes yet. Share an insight, caveat, or question.
Benetti‐Pinto et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: